Russia losing its positions in global drug export market

10 October 2023

Russia is losing its positions in the global drug export market due to difficulties in settlements with foreign partners, caused by sanctions imposed against the country, The Pharma Letter’s local correspondent reports.

According to a recent report of the Russian analytical company in the field of pharmaceutics RNC Pharma, in the first seven months of 2023 exports amounted to 230 million packages, which is the lowest figure in the last six years.

For comparison: during the same period in the pre-Covid years 2018 and 2019, Russia exported 270 million and 300 million packages, respectively. In the first seven months of 2020, shipments increased to a record 390 million packages.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK